The Effect of Atenolol on NT-proBNP and Troponin in Asymptomatic Cats with Severe Left Ventricular Hypertrophy because of Hypertrophic Cardiomyopathy: A Pilot Study

Journal of Veterinary Internal Medicine

Volumn 25, Issue 5, 2011, Pages 1044-1049

  Jung, S W ^a   Kittleson, M D ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Beta blocker; Biomarker; Drug therapy; Myocardial ischemia

Indexed keywords

ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TROPONIN C;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CAT; CAT DISEASE; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTROPHIC CARDIOMYOPATHY; MALE; PILOT STUDY;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANIMALS; ATENOLOL; BIOLOGICAL MARKERS; CARDIOMYOPATHY, HYPERTROPHIC; CAT DISEASES; CATS; FEMALE; HYPERTROPHY, LEFT VENTRICULAR; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PILOT PROJECTS; TROPONIN C;

ANIMALIA;

EID: 80053054291     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2011.0754.x     Document Type: Article

References (37)

1. Abbott JA. Feline hypertrophic cardiomyopathy: An update. Vet Clin North Am Small Anim Pract 2010;40:685-700.
2. Tilley LP, Liu SK, Gilbertson SR, et al. Primary myocardial disease in the cat. A model for human cardiomyopathy. Am J Pathol 1977;86:493-522.
3. Cesta MF, Baty CJ, Keene BW, et al. Pathology of end-stage remodeling in a family of cats with hypertrophic cardiomyopathy. Vet Pathol 2005;42:458-467.
4. Krams R, Kofflard MJ, Duncker DJ, et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 1998;97:230-233.
5. O'Gara PT, Bonow RO, Maron BJ, et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: Assessment with thallium-201 emission computed tomography. Circulation 1987;76:1214-1223.
6. Connolly DJ, Cannata J, Boswood A, et al. Cardiac troponin I in cats with hypertrophic cardiomyopathy. J Feline Med Surg 2003;5:209-216.
7. Herndon WE, Kittleson MD, Sanderson K, et al. Cardiac troponin I in feline hypertrophic cardiomyopathy. J Vet Intern Med 2002;16:558-564.
8. MacDonald KA, Kittleson MD, Kass PH, White SD.Effect of spironolactone on diastolic function and left ventricular mass in Maine Coon cats with familial hypertrophic cardiomyopathy. J Vet Intern Med 2008;22:335-341.
9. Rush JE, Freeman LM, Brown DJ, Smith FWJr. The use of enalapril in the treatment of feline hypertrophic cardiomyopathy. J Am Anim Hosp Assoc 1998;34:38-41.
10. MacDonald KA, Kittleson MD, Larson RF, et al. The effect of ramipril on left ventricular mass, myocardial fibrosis, diastolic function, and plasma neurohormones in Maine Coon cats with familial hypertrophic cardiomyopathy without heart failure. J Vet Intern Med 2006;20:1093-1105.
11. Ozaki K, Sakuma I, Mitsuma K, et al. Effect of cibenzoline and atenolol administration on dynamic left ventricular obstruction due to sigmoid-shaped septum. Circ J 2008;72:2087-2091.
12. Fox PR, Sisson D, Moise NS.Textbook of Canine and Feline Cardiology: Principles and Clinical Practice, 2nd ed. Philadelphia, PA: WB Saunders; 1999: 636.
13. Connolly DJ. Natriuretic peptides: The feline experience. Vet Clin North Am Small Anim Pract 2010;40:559-570.
14. Miller WL, Burnett JCJr, Hartman KA, et al. Role for precursor Pro-B type natriuretic peptide in assessing response to therapy and prognosis in patients with decompensated heart failure treated with nesiritide. Clin Chim Acta 2009;406:119-123.
15. Sisson DD. Neuroendocrine evaluation of cardiac disease. Vet Clin North Am Small Anim Pract 2004;34:1105-1126.
16. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-2116.
17. Howie-Esquivel J, White M.Biomarkers in acute cardiovascular disease. J Cardiovasc Nurs 2008;23:124-131.
18. Liu ZL, Wiedmeyer CE, Sisson DD, Solter PF.Cloning and characterization of feline brain natriuretic peptide. Gene 2002;292:183-190.
19. Goetze JP, Gore A, Moller CH, et al. Acute myocardial hypoxia increases BNP gene expression. FASEB J 2004;18:1928-1930.
20. Ramos LW, Murad N, Goto E, et al. Ischemia/reperfusion is an independent trigger for increasing myocardial content of mRNA B-type natriuretic peptide. Heart Vessels 2009;24:454-459.
21. Connolly DJ, Magalhaes RJ, Syme HM, et al. Circulating natriuretic peptides in cats with heart disease. J Vet Intern Med 2008;22:96-105.
22. Hsu A, Kittleson MD, Paling A.Investigation into the use of plasma NT-proBNP concentration to screen for feline hypertrophic cardiomyopathy. J Vet Cardiol 2009;11(Suppl 1):S63-S70.
23. Singh MK, Cocchiaro MF, Kittleson MD.NT-proBNP measurement fails to reliably identify subclinical hypertrophic cardiomyopathy in Maine Coon cats. J Feline Med Surg 2010;12:942-947.
24. Casals G, Ros J, Sionis A, et al. Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. Am J Physiol Heart Circ Physiol 2009;297:H550-H555.
25. Chun YS, Hyun JY, Kwak YG, et al. Hypoxic activation of the atrial natriuretic peptide gene promoter through direct and indirect actions of hypoxia-inducible factor-1. Biochem J 2003;370:149-157.
26. Jiang C, Lu H, Vincent KA, et al. Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-1 alpha. Physiol Genom 2002;8:23-32.
27. Ruck A, Gustafsson T, Norrbom J, et al. ANP and BNP but not VEGF are regionally overexpressed in ischemic human myocardium. Biochem Biophys Res Commun 2004;322:287-291.
28. Cruickshank JM, McAinsh J.Atenolol and ischaemic heart disease: An overview. Curr Med Res Opin 1991;12:485-496.
29. Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol 2007;120:10-27.
30. Machackova J, Sanganalmath SK, Elimban V, Dhalla NS.Beta-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodeling in congestive heart failure. J Cell Mol Med 2010;15:545-554.
31. Rinfret S, Abrahamowicz M, Tu J, et al. A population-based analysis of the class effect of beta-blockers after myocardial infarction. Am Heart J 2007;153:224-230.
32. Jonsson G, Abdelnoor M, Muller C, et al. A comparison of the two beta-blockers carvedilol and atenolol on left ventricular ejection fraction and clinical endpoints after myocardial infarction. A single-centre, randomized study of 232 patients. Cardiology 2005;103:148-155.
33. Marian AJ. Hypertrophic cardiomyopathy: From genetics to treatment. Eur J Clin Invest 2010;40:360-369.
34. Yu XY, Liu CZ, Wang JH, et al. Brain natriuretic peptide and left ventricular remodeling after emergency percutaneous coronary intervention in acute myocardial infarction patients. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2008;20:204-206.
35. Sartipy U, Albage A, Larsson PT, et al. Changes in B-type natriuretic peptides after surgical ventricular restoration. Eur J Cardiothorac Surg 2007;31:922-928.
36. Bolliger D, Seeberger MD, Lurati Buse GA, et al. A preliminary report on the prognostic significance of preoperative brain natriuretic peptide and postoperative cardiac troponin in patients undergoing major vascular surgery. Anesth Analg 2009;108:1069-1075.
37. Blankenberg S, Zeller T, Saarela O, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: The MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 2010;121:2388-2397.